Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Menin inhibition as a new therapeutic option for the myeloproliferative neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

THTrent HallBMBridget K. MarcellinoGMGerard M. McGeehan

Discussion

Loading...

Member takes

Overview

Inhibition of menin reduces megakaryopoiesis and fibrosis in myeloproliferative neoplasms, improving survival.

Key Points

  • To evaluate menin inhibition as a therapeutic approach for myeloproliferative neoplasms using revumenib.
  • Cultured human CD34+ cells with thrombopoietin and treated with revumenib to assess megakaryocyte lineage.
  • Applied single-cell RNA sequencing to identify impacts on hematopoietic lineage profiles.
  • Investigated therapeutic effects of revumenib in primary MPN samples and mouse models with JAK2 and CALR mutations.
  • Revumenib treatment significantly reduced megakaryocyte progenitor cells and megakaryocytes in vitro and in vivo.
  • Treatment improved survival rates while effectively reducing leukocytes, platelets, and fibrotic features in MPN models.
  • Combined treatment with ruxolitinib further enhanced therapeutic benefits, normalizing blood counts and reducing fibrosis.

Cite This Study

Hall et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cfe6https://doi.org/10.1182/blood-2025-67
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The promise of menin inhibitors: from approval to triplet regimens2025 · 11 citations
  2. 2Therapeutic Implications of Menin Inhibitors in the Treatment of Acute Leukemia: A Critical Review2025 · 7 citations
  3. 3A Phase 1/2 study of the menin inhibitor revumenib with the celmod mezigdomide in relapsed/refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged acute leukemias2025
  4. 4Immunophenotypic changes following menin inhibition in acute myeloid leukemia2026 · 3 citations
  5. 5Menin Inhibition in Acute Myeloid MLL Rearranged Leukemias: A New Target for Precision Care2026 · 3 citations